Elephas Biosciences Corporation, a biotech company that developed an oncology diagnostics platform to predict response to immunotherapy, has raised $41.5 million in a Series B funding round, the company announced today.
According to a release. the round was led by ARCH Venture Partners, with additional or continuing investments by Moore Strategic Ventures and WARF Ventures, among others.
“Our mission at Elephase is to improve care for cancer patients,” Elephas CEO Maneesh Arora said in a statement. “We are grateful for the support of these world-class venture firms who believe in what we are doing and are committed to helping us get there.”